vs

Side-by-side financial comparison of Grindr Inc. (GRND) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $126.0M, roughly 1.6× Grindr Inc.). Grindr Inc. runs the higher net margin — 16.1% vs -62.0%, a 78.1% gap on every dollar of revenue. On growth, Grindr Inc. posted the faster year-over-year revenue change (29.0% vs 25.9%). Grindr Inc. produced more free cash flow last quarter ($24.5M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 29.3%).

Grindr is a location-based social networking and online hookup application for LGBTQ people.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

GRND vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.6× larger
RARE
$207.3M
$126.0M
GRND
Growing faster (revenue YoY)
GRND
GRND
+3.2% gap
GRND
29.0%
25.9%
RARE
Higher net margin
GRND
GRND
78.1% more per $
GRND
16.1%
-62.0%
RARE
More free cash flow
GRND
GRND
$125.3M more FCF
GRND
$24.5M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
29.3%
GRND

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GRND
GRND
RARE
RARE
Revenue
$126.0M
$207.3M
Net Profit
$20.3M
$-128.6M
Gross Margin
Operating Margin
24.9%
-54.7%
Net Margin
16.1%
-62.0%
Revenue YoY
29.0%
25.9%
Net Profit YoY
116.4%
3.5%
EPS (diluted)
$0.10
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GRND
GRND
RARE
RARE
Q4 25
$126.0M
$207.3M
Q3 25
$115.8M
$159.9M
Q2 25
$104.2M
$166.5M
Q1 25
$93.9M
$139.3M
Q4 24
$97.6M
$164.6M
Q3 24
$89.3M
$139.5M
Q2 24
$82.3M
$147.0M
Q1 24
$75.3M
$108.8M
Net Profit
GRND
GRND
RARE
RARE
Q4 25
$20.3M
$-128.6M
Q3 25
$30.8M
$-180.4M
Q2 25
$16.6M
$-115.0M
Q1 25
$27.0M
$-151.1M
Q4 24
$-123.9M
$-133.2M
Q3 24
$24.7M
$-133.5M
Q2 24
$-22.4M
$-131.6M
Q1 24
$-9.4M
$-170.7M
Operating Margin
GRND
GRND
RARE
RARE
Q4 25
24.9%
-54.7%
Q3 25
39.1%
-106.9%
Q2 25
23.4%
-64.8%
Q1 25
27.0%
-102.6%
Q4 24
20.9%
-74.3%
Q3 24
31.8%
-94.6%
Q2 24
29.8%
-79.1%
Q1 24
25.6%
-151.9%
Net Margin
GRND
GRND
RARE
RARE
Q4 25
16.1%
-62.0%
Q3 25
26.6%
-112.8%
Q2 25
16.0%
-69.0%
Q1 25
28.8%
-108.5%
Q4 24
-126.9%
-80.9%
Q3 24
27.6%
-95.7%
Q2 24
-27.2%
-89.5%
Q1 24
-12.5%
-156.8%
EPS (diluted)
GRND
GRND
RARE
RARE
Q4 25
$0.10
$-1.28
Q3 25
$0.16
$-1.81
Q2 25
$0.08
$-1.17
Q1 25
$0.09
$-1.57
Q4 24
$-0.65
$-1.34
Q3 24
$0.09
$-1.40
Q2 24
$-0.13
$-1.52
Q1 24
$-0.05
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GRND
GRND
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$87.0M
$421.0M
Total DebtLower is stronger
$395.9M
Stockholders' EquityBook value
$47.0M
$-80.0M
Total Assets
$531.0M
$1.5B
Debt / EquityLower = less leverage
8.42×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GRND
GRND
RARE
RARE
Q4 25
$87.0M
$421.0M
Q3 25
$6.3M
$202.5M
Q2 25
$120.8M
$176.3M
Q1 25
$255.9M
$127.1M
Q4 24
$59.2M
$174.0M
Q3 24
$39.1M
$150.6M
Q2 24
$16.3M
$480.7M
Q1 24
$21.5M
$112.3M
Total Debt
GRND
GRND
RARE
RARE
Q4 25
$395.9M
Q3 25
$279.9M
Q2 25
$283.5M
Q1 25
$287.0M
Q4 24
$290.6M
Q3 24
$294.1M
Q2 24
$297.7M
Q1 24
$315.0M
Stockholders' Equity
GRND
GRND
RARE
RARE
Q4 25
$47.0M
$-80.0M
Q3 25
$71.0M
$9.2M
Q2 25
$187.7M
$151.3M
Q1 25
$319.8M
$144.2M
Q4 24
$-131.6M
$255.0M
Q3 24
$-13.4M
$346.8M
Q2 24
$-41.7M
$432.4M
Q1 24
$-22.0M
$140.3M
Total Assets
GRND
GRND
RARE
RARE
Q4 25
$531.0M
$1.5B
Q3 25
$439.2M
$1.2B
Q2 25
$547.6M
$1.3B
Q1 25
$679.4M
$1.3B
Q4 24
$479.1M
$1.5B
Q3 24
$456.3M
$1.5B
Q2 24
$435.0M
$1.6B
Q1 24
$437.7M
$1.3B
Debt / Equity
GRND
GRND
RARE
RARE
Q4 25
8.42×
Q3 25
3.94×
Q2 25
1.51×
Q1 25
0.90×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GRND
GRND
RARE
RARE
Operating Cash FlowLast quarter
$24.8M
$-99.8M
Free Cash FlowOCF − Capex
$24.5M
$-100.8M
FCF MarginFCF / Revenue
19.5%
-48.6%
Capex IntensityCapex / Revenue
0.2%
0.5%
Cash ConversionOCF / Net Profit
1.22×
TTM Free Cash FlowTrailing 4 quarters
$140.8M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GRND
GRND
RARE
RARE
Q4 25
$24.8M
$-99.8M
Q3 25
$55.4M
$-91.4M
Q2 25
$37.5M
$-108.3M
Q1 25
$23.8M
$-166.5M
Q4 24
$29.5M
$-79.3M
Q3 24
$29.1M
$-67.0M
Q2 24
$15.8M
$-77.0M
Q1 24
$20.4M
$-190.7M
Free Cash Flow
GRND
GRND
RARE
RARE
Q4 25
$24.5M
$-100.8M
Q3 25
$55.2M
$-92.7M
Q2 25
$37.3M
$-110.7M
Q1 25
$23.7M
$-167.8M
Q4 24
$29.3M
$-79.5M
Q3 24
$28.8M
$-68.6M
Q2 24
$15.7M
$-79.0M
Q1 24
$20.3M
$-193.9M
FCF Margin
GRND
GRND
RARE
RARE
Q4 25
19.5%
-48.6%
Q3 25
47.7%
-58.0%
Q2 25
35.8%
-66.5%
Q1 25
25.2%
-120.5%
Q4 24
30.0%
-48.3%
Q3 24
32.2%
-49.2%
Q2 24
19.0%
-53.7%
Q1 24
26.9%
-178.2%
Capex Intensity
GRND
GRND
RARE
RARE
Q4 25
0.2%
0.5%
Q3 25
0.2%
0.8%
Q2 25
0.2%
1.5%
Q1 25
0.1%
1.0%
Q4 24
0.3%
0.1%
Q3 24
0.4%
1.2%
Q2 24
0.2%
1.4%
Q1 24
0.3%
3.0%
Cash Conversion
GRND
GRND
RARE
RARE
Q4 25
1.22×
Q3 25
1.80×
Q2 25
2.25×
Q1 25
0.88×
Q4 24
Q3 24
1.18×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GRND
GRND

License And Service$102.9M82%
Advertising$23.1M18%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons